KIT突变与CD117过表达提示外阴黑色素瘤无进展生存更优
本研究对95例外阴黑色素瘤进行免疫组化及分子检测,发现KIT突变(44%)、BRAF突变(25%)等。单因素分析显示KIT突变与更好的无进展生存显著相关,多因素分析显示CD117表达与更好的无进展生存显著相关。肿瘤厚度与更差的无进展生存和总生存显著相关,神经周围侵犯与更差的黑色素瘤特异性生存和总生存显著相关。
要点
- KIT突变在外阴黑色素瘤中占44%,与更好的无进展生存显著相关。
- CD117过表达在多因素分析中与更好的无进展生存显著相关。
- 肿瘤厚度和神经周围侵犯是预后不良因素。
核心结论
- KIT突变和CD117过表达是外阴黑色素瘤无进展生存更好的标志物。
研究设计与样本
- 对95例外阴黑色素瘤的临床病理特征进行回顾性分析,并进行p53、CD117、Ki-67、神经纤维蛋白、BRAF V600E和NRAS Q61R免疫组化及靶向下一代测序或直接测序。
主要发现
- 分子检测发现KIT突变44%、BRAF突变25%、NF1突变22%、TP53突变17%、NRAS突变9%、TERT启动子突变9%。
- 单因素分析显示KIT突变与更好的无进展生存显著相关。
- 多因素分析显示CD117表达与更好的无进展生存显著相关。
- 肿瘤厚度与更差的无进展生存和总生存显著相关。
- 神经周围侵犯与更差的黑色素瘤特异性生存和总生存显著相关。
临床怎么用
- 外阴黑色素瘤患者可考虑进行分子检测,以评估预后并识别可能对靶向治疗或免疫治疗应答的病例。
局限性
- 病例来自多个中心,且仅部分样本可用于分子检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Few studies have addressed prognostic markers and none has correlated molecular status and prognosis in vulvar melanomas. OBJECTIVES: To evaluate the clinicopathological features of 95 cases of vulvar melanoma. METHODS: p53, CD117, Ki-67, neurofibromin, brafv600e and nrasq61r immunostains, and molecular analyses by either targeted next-generation or direct sequencing, were performed on available archival materials. RESULTS: Molecular testing detected mutations in KIT (44%), BRAF (25%), NF1 (22%), TP53 (17%), NRAS (9%) and TERT promoter (9%). Co-mutation of KIT and NF1 and of KIT and NRAS were identified in two and one cases, respectively. KIT mutations were significantly associated with better progression-free survival in univariate analyses. In multivariate analyses CD117 expression was significantly associated with better progression-free survival. Tumour thickness was significantly associated with worse progression-free and overall survival, and perineural invasion significantly correlated with reduced melanoma-specific survival and reduced overall survival. Cases were from multiple centres and only a subset of samples was available for molecular testing. CONCLUSIONS: KIT mutations and CD117 overexpression are markers of better progression-free survival. In addition to its prognostic value, molecular testing may identify cases that might respond to targeted agents or immunotherapeutic approaches.
引用
- Dias-Santagata D, Selim MA, Su Y, et al. KIT mutations and CD117 overexpression are markers of better progression-free survival in vulvar melanomas. Br J Dermatol. 2017. PMID: 28734009. doi:10.1111/bjd.15836
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。